849. Small Molecules, Big Trouble
Session: Symposium: Novel Clinical Risks for Fungal Disease
Thursday, October 4, 2018: 2:25 PM
Room: W 2014-2016
Michail Lionakis, M.D., Sc.D., National Institute of Allergy and Infectious Diseases, Bethesda, MD

I am a physician-scientist and Head of the Fungal Pathogenesis Section in the Laboratory of Clinical Immunology and Microbiology, NIAID. My laboratory research focuses on 1) better understanding the genetic and immune defects that underlie enhanced susceptibility to mucocutaneous and invasive fungal infections in humans and on 2) cellular and molecular factors that regulate the immune response against mucosal and invasive candidiasis and invasive aspergillosis in clinically relevant animal models. Our long-term goals are 1) to understand the pathogenesis of mucosal and invasive candidiasis and invasive aspergillosis, 2) to use this knowledge to identify patients at risk for developing these diseases and to improve their outcomes, 3) to improve care for patients with inherited susceptibility to fungal disease such as Autoimmune Polyendocrinopathy-Candidiasis-Ectodermal Dystrophy (APECED), Caspase recruitment domain-containing protein 9 (CARD9) deficiency and others, and 4) to discover novel genetic predisposing factors for human fungal disease. To this end, we utilize in vitro cell culture systems and clinically relevant mouse models of mucosal and systemic Candida infections and pulmonary Aspergillus infections, and we enroll patients with inherited and acquired susceptibility to candidiasis and aspergillosis to study host-fungal interactions by using a variety of immunological, biological, and imaging approaches.


Disclosures:

M. Lionakis, None

Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 3rd with the exception of research findings presented at the IDWeek press conferences.